Phathom Voquezna Expansion Strategy Poised To Deliver In GERD

The acid reducer was approved by the US FDA for a substantially larger indication in non-erosive gastroesophageal reflux disease but will have to prove itself commercially against PPIs.

Phathom is looking to take on PPIs for GERD • Source: Shutterstock

Phathom Pharmaceuticals, Inc. already launched the heartburn reliever Voquezna (vonoprazan) in November 2023, but US Food and Drug Administration approval in an expanded indication will make the treatment available to a substantially larger set of patients. The FDA approved Voquezna on 17 July for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults, a condition that affects millions of individuals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

18 Apr 2025

• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

16 Apr 2025

• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

14 Apr 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.